Answers are grounded in this paper and cite their sources.
This review critically examines the dual clinical and environmental imperatives associated with metered-dose inhalers (MDIs) in the context of sustainable healthcare. A comprehensive literature review was conducted using databases including PubMed, Scopus, Web of Science, and ScienceDirect, focusing on publications related to inhaler propellants, life-cycle environmental impact, regulatory transitions, and emerging low-global-warming-potential (GWP) technologies. Although the healthcare sector contributes approximately 4.5% of global greenhouse gas emissions, MDIs account for only about 0.03% of annual global emissions. Nevertheless, their high-GWP propellants make them a focal point for decarbonization strategies. The review highlights the historical transition from chlorofluorocarbons (CFCs) to hydrofluoroalkanes (HFAs), evaluates the life-cycle carbon footprint of MDIs, and discusses emerging alternatives such as low-GWP propellants including HFC-152a and HFO-1234ze(E). In parallel, propellant-free inhalation technologies, eco-design principles, renewable energy integration in manufacturing, and circular supply-chain approaches are identified as key enablers of sustainability. Advances in propellant chemistry, device engineering, and manufacturing sustainability demonstrate that meaningful reductions in the environmental impact of inhalation therapy are achievable. Aligning respiratory care with global climate objectives is both ethically necessary and technically feasible, without compromising therapeutic efficacy or patient outcomes.
No takes yet. Share an insight, caveat, or question.
Vishwakarma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: